Naloxone Polpharma (Naloxone Hydrochloride)

Naloxone, the active ingredient in Naloxone Polpharma, is an opioid antagonist presented as a sterile solution for intramuscular, intravenous, and subcutaneous use. It rapidly reverses opioid‑induced respiratory depression in emergency situations. GNH USA supplies Naloxone Polpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Naloxone is an opioid antagonist used in the management of opioid overdose and related emergencies.

- Opioid overdose: rapidly reverses respiratory depression and restores consciousness. - Opioid toxicity: counteracts life‑threatening effects of excess opioid activity. - Opioid‑induced sedation: restores normal breathing and alertness.

Naloxone is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea - Vomiting - Sweating - Headache - Tachycardia - Hypertension

Serious or Rare Side Effects: - Seizures - Severe hypertension or arrhythmias - Pulmonary edema - Anaphylactic reaction - Local injection site necrosis - Acute opioid withdrawal syndrome

Naloxone should be administered with careful clinical assessment and monitoring. - Airway assessment: ensure airway patency before injection. - Withdrawal risk: be aware of precipitated opioid withdrawal in dependent patients. - Cardiovascular monitoring: watch for rapid changes in blood pressure and heart rate. - Injection technique: avoid intravascular administration when possible. - Indication confirmation: use only when opioid overdose is suspected. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Naloxone may interact with other medications that affect the cardiovascular or central nervous systems.

Major Interactions (Avoid): - Mixed agonist‑antagonist opioids (e.g., buprenorphine) may precipitate severe withdrawal. - High‑dose catecholamines can exacerbate hypertension after naloxone administration. - Beta‑blockers may mask tachycardia caused by naloxone.

Moderate Interactions (Monitor Closely): - Sedatives or CNS depressants may enhance residual sedation after naloxone. - Antihypertensive agents may require dose adjustment due to sudden blood pressure rise. - Tricyclic antidepressants can increase the risk of cardiac arrhythmias when combined with naloxone‑induced tachycardia.